HPD

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, HPD Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated HPD data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HPD Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HPD expression acts as an unfavorable survival marker.

HNSC, SARC, and GBM are the cancer types where HPD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
HNSCDFSMedianAll0.0940.710<.00118view →
SARCOSMedianAll0.2410.766.0226view →
GBMOSMedianAll0.0890.413.0156view →
Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

HPD–HNSC (DFS)

Kaplan–Meier survival curve for HPD mutant vs wild-type samples in HNSC.

Open the HNSC breakdown →

Exploration